Cymbalta: Dual-Action Relief for Chronic Pain and Depression
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.54 | $46.21 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $92.41 $65.29 (29%) | 🛒 Add to cart |
| 90 | $0.93 | $138.62 $83.37 (40%) | 🛒 Add to cart |
| 120 | $0.85 | $184.82 $101.45 (45%) | 🛒 Add to cart |
| 180 | $0.78 | $277.24 $139.62 (50%) | 🛒 Add to cart |
| 270 | $0.73 | $415.85 $195.87 (53%) | 🛒 Add to cart |
| 360 | $0.69
Best per pill | $554.47 $250.12 (55%) | 🛒 Add to cart |
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.51 | $75.34 (0%) | 🛒 Add to cart |
| 60 | $1.77 | $150.67 $106.47 (29%) | 🛒 Add to cart |
| 90 | $1.53 | $226.01 $137.61 (39%) | 🛒 Add to cart |
| 120 | $1.41 | $301.34 $168.75 (44%) | 🛒 Add to cart |
| 180 | $1.28 | $452.02 $231.03 (49%) | 🛒 Add to cart |
| 270 | $1.20
Best per pill | $678.02 $324.45 (52%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.75 | $82.37 (0%) | 🛒 Add to cart |
| 60 | $1.98 | $164.73 $118.53 (28%) | 🛒 Add to cart |
| 90 | $1.71 | $247.10 $153.69 (38%) | 🛒 Add to cart |
| 120 | $1.58 | $329.47 $189.85 (42%) | 🛒 Add to cart |
| 180 | $1.45 | $494.20 $261.16 (47%) | 🛒 Add to cart |
| 270 | $1.37
Best per pill | $741.31 $370.65 (50%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.38 | $101.45 (0%) | 🛒 Add to cart |
| 60 | $2.65 | $202.90 $158.71 (22%) | 🛒 Add to cart |
| 90 | $2.41 | $304.36 $216.97 (29%) | 🛒 Add to cart |
| 120 | $2.29 | $405.81 $274.22 (32%) | 🛒 Add to cart |
| 180 | $2.17 | $608.71 $389.74 (36%) | 🛒 Add to cart |
| 270 | $2.09
Best per pill | $913.07 $563.51 (38%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Cymbalta (duloxetine) is a prescription medication classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). It is clinically proven to manage major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. By increasing the levels of serotonin and norepinephrine in the brain, Cymbalta helps restore chemical balance, which can improve mood, reduce anxiety, and alleviate chronic pain signals. This dual mechanism offers a comprehensive therapeutic approach for conditions that often coexist, providing patients with a potential path toward improved daily functioning and quality of life.
Features
- Active ingredient: Duloxetine hydrochloride
- Available in delayed-release capsules: 20 mg, 30 mg, 60 mg
- SNRI class medication with dual reuptake inhibition
- FDA-approved for multiple indications: MDD, GAD, chronic pain conditions
- Once-daily oral administration
- Designed for gradual dose titration
Benefits
- Provides effective relief from symptoms of major depressive disorder
- Reduces pervasive anxiety associated with generalized anxiety disorder
- Alleviates chronic neuropathic pain, including diabetic peripheral neuropathy
- Improves overall quality of life and functional capacity in fibromyalgia patients
- Offers convenient once-daily dosing for treatment adherence
- Addresses both emotional and physical symptoms through dual neurotransmitter action
Common use
Cymbalta is commonly prescribed for the management of major depressive disorder in adults, providing relief from persistent sadness, loss of interest, and other depressive symptoms. It is also widely used for generalized anxiety disorder, helping reduce excessive worry, tension, and associated physical symptoms. Additionally, Cymbalta is indicated for the management of chronic pain conditions, including diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (such as chronic low back pain and osteoarthritis pain). The medication works by modulating pain pathways in the central nervous system, making it particularly valuable for patients with both mood disorders and chronic pain.
Dosage and direction
The recommended starting dose for most indications is 30 mg once daily for one week, followed by an increase to 60 mg once daily, which is the effective dose for most patients. For some patients with fibromyalgia or chronic musculoskeletal pain, doses up to 120 mg per day have been studied, though the 60 mg dose remains standard for most indications. The capsules should be swallowed whole and not chewed, crushed, or opened, as this may affect the delayed-release properties. Administration with food may minimize potential gastrointestinal side effects. Dose adjustments are necessary for patients with hepatic impairment or severe renal impairment. Abrupt discontinuation should be avoided; instead, a gradual taper is recommended under medical supervision.
Precautions
Patients should be monitored for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of therapy and during dose adjustments. Cymbalta may increase the risk of bleeding; caution is advised in patients taking anticoagulants or with underlying bleeding disorders. Blood pressure monitoring is recommended, as duloxetine can increase blood pressure in some patients. Use with caution in patients with a history of mania or hypomania, as antidepressants may precipitate a manic episode. Patients with controlled narrow-angle glaucoma should be monitored regularly. Hepatic function should be assessed periodically during treatment, as duloxetine is extensively metabolized in the liver.
Contraindications
Cymbalta is contraindicated in patients with known hypersensitivity to duloxetine or any of the inactive ingredients. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome; at least 14 days should elapse between discontinuing an MAOI and initiating Cymbalta therapy. Similarly, a minimum 5-day washout period is recommended after stopping Cymbalta before starting an MAOI. The medication is contraindicated in patients with uncontrolled narrow-angle glaucoma. Use is not recommended in patients with end-stage renal disease or severe renal impairment (CrCl <30 mL/min).
Possible side effect
Common side effects include nausea (occurring in approximately 20-30% of patients), dry mouth, constipation, decreased appetite, fatigue, drowsiness, and increased sweating. These effects are often transient and may diminish with continued treatment. Less frequently, patients may experience dizziness, insomnia, blurred vision, or sexual dysfunction. Serious side effects requiring immediate medical attention include signs of liver problems (dark urine, jaundice), serotonin syndrome (agitation, hallucinations, fever, tachycardia), abnormal bleeding, severe skin reactions, or symptoms of hyponatremia (headache, difficulty concentrating, confusion). Approximately 1% of patients may experience elevation in blood pressure.
Drug interaction
Cymbalta has significant interactions with MAOIs, potentially causing serotonin syndrome or neuroleptic malignant syndrome-like reactions. Strong inhibitors of CYP1A2 (such as fluvoxamine) may increase duloxetine concentrations. Concomitant use with other serotonergic drugs (triptans, tramadol, tryptophan) increases serotonin syndrome risk. NSAIDs, aspirin, or warfarin coadministration may increase bleeding risk. Duloxetine may interact with drugs that are highly protein-bound, potentially increasing free concentrations of either medication. Use with caution alongside other CNS-acting drugs, including alcohol, which may enhance cognitive and motor effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling up on doses to make up for a missed dose is not recommended, as this may increase the risk of side effects. Patients should maintain a consistent dosing schedule to ensure stable medication levels and optimal therapeutic effect. Setting daily reminders or using pill organizers can help improve adherence to the prescribed regimen.
Overdose
Symptoms of duloxetine overdose may include serotonin syndrome manifestations (agitation, hallucinations, coma), tachycardia, hypotension, syncope, seizures, vomiting, or somnolence. In cases of suspected overdose, immediate medical attention is required. There is no specific antidote for duloxetine overdose; treatment consists of supportive measures and symptomatic management. Gastric lavage may be considered if performed soon after ingestion. Activated charcoal may help reduce absorption. Monitoring of cardiac function and vital signs is essential, along with appropriate symptomatic treatment for any clinical manifestations.
Storage
Cymbalta capsules should be stored at room temperature (20-25°C or 68-77°F), with excursions permitted between 15-30°C (59-86°F). The medication should be kept in its original container, tightly closed, and protected from moisture and light. It should be stored out of reach of children and pets. Unused medication should be disposed of properly through medication take-back programs or according to FDA-recommended disposal methods (mixing with undesirable substance in sealed container). The medication should not be flushed down the toilet unless specifically instructed to do so.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Cymbalta is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary, and only a healthcare provider can determine the appropriate treatment based on a patient’s specific medical condition, history, and current medications. Patients should not initiate, adjust, or discontinue Cymbalta without consulting their healthcare provider. The complete prescribing information should be reviewed before starting treatment.
Reviews
Clinical studies demonstrate that Cymbalta provides significant improvement in depression and anxiety symptoms, with response rates typically observed within 1-2 weeks for some symptoms and full therapeutic effect within 4-8 weeks. For pain conditions, patients often report meaningful pain relief and improved function. Many patients appreciate the dual benefit for coexisting mood and pain symptoms. Some users report initial side effects that often diminish over time, while others find the medication well-tolerated from the start. Healthcare providers frequently note the medication’s effectiveness in treatment-resistant cases and its value in treating the complex interplay between chronic pain and depression.